Migraine management: an update for the 2020s

Migraine is a common malady cutting across socioeconomic and ethnic divides in Australia. It is typically diagnosed late with significant impact on quality of life. Management options have emerged over the past several years that promise simpler treatment regimens with less potential for side‐effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Eller, Michael, Cheng, Shuli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Clinical Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545433/
https://www.ncbi.nlm.nih.gov/pubmed/35879242
http://dx.doi.org/10.1111/imj.15843
_version_ 1784804820418297856
author Eller, Michael
Cheng, Shuli
author_facet Eller, Michael
Cheng, Shuli
author_sort Eller, Michael
collection PubMed
description Migraine is a common malady cutting across socioeconomic and ethnic divides in Australia. It is typically diagnosed late with significant impact on quality of life. Management options have emerged over the past several years that promise simpler treatment regimens with less potential for side‐effects. The development of rationally designed migraine preventives is the most significant advance in treatment since the development of the triptans and delivers significant hope to many headache sufferers.
format Online
Article
Text
id pubmed-9545433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-95454332022-10-14 Migraine management: an update for the 2020s Eller, Michael Cheng, Shuli Intern Med J Clinical Perspectives Migraine is a common malady cutting across socioeconomic and ethnic divides in Australia. It is typically diagnosed late with significant impact on quality of life. Management options have emerged over the past several years that promise simpler treatment regimens with less potential for side‐effects. The development of rationally designed migraine preventives is the most significant advance in treatment since the development of the triptans and delivers significant hope to many headache sufferers. John Wiley & Sons Australia, Ltd 2022-07-25 2022-07 /pmc/articles/PMC9545433/ /pubmed/35879242 http://dx.doi.org/10.1111/imj.15843 Text en © 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Clinical Perspectives
Eller, Michael
Cheng, Shuli
Migraine management: an update for the 2020s
title Migraine management: an update for the 2020s
title_full Migraine management: an update for the 2020s
title_fullStr Migraine management: an update for the 2020s
title_full_unstemmed Migraine management: an update for the 2020s
title_short Migraine management: an update for the 2020s
title_sort migraine management: an update for the 2020s
topic Clinical Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545433/
https://www.ncbi.nlm.nih.gov/pubmed/35879242
http://dx.doi.org/10.1111/imj.15843
work_keys_str_mv AT ellermichael migrainemanagementanupdateforthe2020s
AT chengshuli migrainemanagementanupdateforthe2020s

Ejemplares similares